Pawlikowska-Dobler, Iwona
Mayo Clinic
Millennium Pharmaceuticals, Inc., Cambridge, MA; and.
Citations 1
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Swords, Ronan , Maris, Michael B., Zeidner, Joshua F. , Foran, James M. , Cruz, José C. , Tam, Wayne , Vardhanabhuti, Saran , Pawlikowska-Dobler, Iwona , Faessel, Hélène M. , Dash, Ajeeta B. , Sedarati, Farhad , Dezube, Bruce J., Faller, Douglas V. , Swords, Ronan T , Zeidner, Joshua F , Cruz, Jose , Tam, Wayne , Vardhanabhuti, Saran , Pawlikowska-Dobler, Iwona , Dash, Ajeeta B , Sedarati, Farhad , Faller, Douglas V , Savona, Michael R , Coutré, Steven , Erba, Harry Paul , Berdeja, Jesús G. , Savona, Michael R.
Blood | January 18, 2018 | Volume: 131 | Issue: 13 | Pages: 1415-1424
Key Points RP2D of PEV 20 mg/m2 in PEV/AZA combo did not alter toxicity profile of AZA; dose-limiting toxicities were transiently elevated AST/ALT. In treatment-naive older AML patients, the intent-to-treat ORR was 50%.